Seventeen out of twenty-three moderate PD patients (eight patients with GBA mutations and nine without GBA mutations) received an escalating dose of oral ABX up to 1.26 g per day over 6 months, without serious adverse events. This evidence concerns the gene GBA1 and Parkinson disease.